Fusion Gene Studies
in Kim Lab

FusionBase FusionGDB FusionGDB2 FusionPDB FusionNeoAntigen FusionAI FusionNW FGviewer Publication Contact
FusionGDB Logo

Home

Download

Statistics

Examples

Help

Contact

Center for Computational Systems Medicine
leaf

Fusion Gene Summary

leaf

Fusion Gene ORF analysis

leaf

Fusion Genomic Features

leaf

Fusion Protein Features

leaf

Fusion Gene Sequence

leaf

Fusion Gene PPI analysis

leaf

Related Drugs

leaf

Related Diseases

Fusion gene:BRAF-CIITA (FusionGDB2 ID:HG673TG4261)

Fusion Gene Summary for BRAF-CIITA

check button Fusion gene summary
Fusion gene informationFusion gene name: BRAF-CIITA
Fusion gene ID: hg673tg4261
HgeneTgene
Gene symbol

BRAF

CIITA

Gene ID

673

4261

Gene nameB-Raf proto-oncogene, serine/threonine kinaseclass II major histocompatibility complex transactivator
SynonymsB-RAF1|B-raf|BRAF1|NS7|RAFB1C2TA|CIITAIV|MHC2TA|NLRA
Cytomap('BRAF')('CIITA')

7q34

16p13.13

Type of geneprotein-codingprotein-coding
Descriptionserine/threonine-protein kinase B-raf94 kDa B-raf proteinB-Raf proto-oncogene serine/threonine-protein kinase (p94)B-Raf serine/threonine-proteinmurine sarcoma viral (v-raf) oncogene homolog B1proto-oncogene B-Rafv-raf murine sarcoma viral oncogene MHC class II transactivatorMHC class II transactivator type IMHC class II transactivator type IIINLR family, acid domain containingnucleotide-binding oligomerization domain, leucine rich repeat and acid domain containing
Modification date2020032920200320
UniProtAcc

P15056

.
Ensembl transtripts involved in fusion geneENST00000288602, 
Fusion gene scores* DoF score28 X 21 X 11=64687 X 7 X 6=294
# samples 327
** MAII scorelog2(32/6468*10)=-4.3371758685863
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/294*10)=-2.0703893278914
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Context

PubMed: BRAF [Title/Abstract] AND CIITA [Title/Abstract] AND fusion [Title/Abstract]

Most frequent breakpointBRAF(140487348)-CIITA(10995371), # samples:1
Anticipated loss of major functional domain due to fusion event.BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
BRAF-CIITA seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneBRAF

GO:0000186

activation of MAPKK activity

29433126

HgeneBRAF

GO:0006468

protein phosphorylation

17563371

HgeneBRAF

GO:0010828

positive regulation of glucose transmembrane transport

23010278

HgeneBRAF

GO:0033138

positive regulation of peptidyl-serine phosphorylation

19667065

HgeneBRAF

GO:0043066

negative regulation of apoptotic process

19667065

HgeneBRAF

GO:0070374

positive regulation of ERK1 and ERK2 cascade

22065586

HgeneBRAF

GO:0071277

cellular response to calcium ion

18567582

HgeneBRAF

GO:0090150

establishment of protein localization to membrane

23010278

TgeneCIITA

GO:0034341

response to interferon-gamma

19041327

TgeneCIITA

GO:0045345

positive regulation of MHC class I biosynthetic process

20639463

TgeneCIITA

GO:0045892

negative regulation of transcription, DNA-templated

19041327

TgeneCIITA

GO:0045893

positive regulation of transcription, DNA-templated

19041327

TgeneCIITA

GO:0045944

positive regulation of transcription by RNA polymerase II

20639463

TgeneCIITA

GO:0046677

response to antibiotic

107465


check buttonFusion gene breakpoints across BRAF (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure
check buttonFusion gene breakpoints across CIITA (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check button Fusion gene information
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
SourceDiseaseSampleHgeneHchrHbpHstrandTgeneTchrTbpTstrand
ChimerDB4THCATCGA-EM-A3AQ-01ABRAFchr7

140487348

-CIITAchr16

10995371

+


Top

Fusion Gene ORF analysis for BRAF-CIITA

check button Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.
ORFHenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrand
5CDS-3UTRENST00000288602ENST00000537380BRAFchr7

140487348

-CIITAchr16

10995371

+
In-frameENST00000288602ENST00000324288BRAFchr7

140487348

-CIITAchr16

10995371

+
In-frameENST00000288602ENST00000381835BRAFchr7

140487348

-CIITAchr16

10995371

+

check buttonORFfinder result based on the fusion transcript sequence of in-frame fusion genes.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000288602BRAFchr7140487348-ENST00000324288CIITAchr1610995371+1010712386141941377
ENST00000288602BRAFchr7140487348-ENST00000381835CIITAchr1610995371+30251238612442793

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000288602ENST00000324288BRAFchr7140487348-CIITAchr1610995371+0.0010948130.9989052
ENST00000288602ENST00000381835BRAFchr7140487348-CIITAchr1610995371+0.0069721530.99302787

Top

Fusion Genomic Features for BRAF-CIITA


check buttonFusionAI prediction of the potential fusion gene breakpoint based on the pre-mature RNA sequence context (+/- 5kb of individual partner genes, total 20kb length sequence). FusionAI is a fusion gene breakpoint classifier based on convolutional neural network by comparing the fusion positive and negative sequence context of ~ 20K fusion gene data. From here, we can have the relative potentency of the 20K genomic sequence how individual sequnce will be likely used as the gene fusion breakpoints.
HgeneHchrHbpHstrandTgeneTchrTbpTstrand1-pp (fusion gene breakpoint)
BRAFchr7140487347-CIITAchr1610995370+3.07E-050.99996924
BRAFchr7140487347-CIITAchr1610995370+3.07E-050.99996924

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions. We integrated a total of 44 different types of human genomic feature loci information across five big categories including virus integration sites, repeats, structural variants, chromatin states, and gene expression regulation. More details are in help page.
genomic feature

check buttonDistribution of 44 human genomic features loci across 20kb length fusion breakpoint regions that are ovelapped with the top 1% feature importance score regions. More details are in help page.
genomic feature of top 1%

Top

Fusion Protein Features for BRAF-CIITA


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr7:140487348/chr16:10995371)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonMain function of each fusion partner protein. (from UniProt)
HgeneTgene
BRAF

P15056

.
FUNCTION: Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179). {ECO:0000269|PubMed:1508179, ECO:0000269|PubMed:21441910, ECO:0000269|PubMed:29433126, ECO:0000305}.FUNCTION: Transcriptional activator which is required for calcium-dependent dendritic growth and branching in cortical neurons. Recruits CREB-binding protein (CREBBP) to nuclear bodies. Component of the CREST-BRG1 complex, a multiprotein complex that regulates promoter activation by orchestrating a calcium-dependent release of a repressor complex and a recruitment of an activator complex. In resting neurons, transcription of the c-FOS promoter is inhibited by BRG1-dependent recruitment of a phospho-RB1-HDAC1 repressor complex. Upon calcium influx, RB1 is dephosphorylated by calcineurin, which leads to release of the repressor complex. At the same time, there is increased recruitment of CREBBP to the promoter by a CREST-dependent mechanism, which leads to transcriptional activation. The CREST-BRG1 complex also binds to the NR2B promoter, and activity-dependent induction of NR2B expression involves a release of HDAC1 and recruitment of CREBBP (By similarity). {ECO:0000250}.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at

download page


* Minus value of BPloci means that the break pointn is located before the CDS.
- In-frame and retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918122_129392767.0Compositional biasNote=Poly-Ser
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-9186_11392767.0Compositional biasNote=Poly-Gly
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918155_227392767.0DomainRBD
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918234_280392767.0Zinc fingerPhorbol-ester/DAG-type
TgeneCIITAchr7:140487348chr16:10995371ENST00000324288420414_7241453032.6666666666665DomainNACHT
TgeneCIITAchr7:140487348chr16:10995371ENST00000324288420420_4271453032.6666666666665Nucleotide bindingNote=GTP
TgeneCIITAchr7:140487348chr16:10995371ENST000003242884201016_10371453032.6666666666665RepeatNote=LRR 2
TgeneCIITAchr7:140487348chr16:10995371ENST000003242884201045_10661453032.6666666666665RepeatNote=LRR 3
TgeneCIITAchr7:140487348chr16:10995371ENST000003242884201073_10931453032.6666666666665RepeatNote=LRR 4
TgeneCIITAchr7:140487348chr16:10995371ENST00000324288420985_10081453032.6666666666665RepeatNote=LRR 1

- In-frame and not-retained protein feature among the 13 regional features.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918428_432392767.0Compositional biasNote=Poly-Ser
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918457_717392767.0DomainProtein kinase
HgeneBRAFchr7:140487348chr16:10995371ENST00000288602-918463_471392767.0Nucleotide bindingATP
TgeneCIITAchr7:140487348chr16:10995371ENST0000032428842052_1371453032.6666666666665Compositional biasNote=Asp/Glu-rich (acidic)
TgeneCIITAchr7:140487348chr16:10995371ENST0000032428842094_1321453032.6666666666665RegionNote=Required for acetyltransferase activity


Top

Fusion Gene Sequence for BRAF-CIITA


check button For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. To have fusion amino acid sequence, we ran ORFfinder and chose the longest ORF among the all predicted ones.
>10118_10118_1_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000324288_length(transcript)=10107nt_BP=1238nt
CGCCTCCCTTCCCCCTCCCCGCCCGACAGCGGCCGCTCGGGCCCCGGCTCTCGGTTATAAGATGGCGGCGCTGAGCGGTGGCGGTGGTGG
CGGCGCGGAGCCGGGCCAGGCTCTGTTCAACGGGGACATGGAGCCCGAGGCCGGCGCCGGCGCCGGCGCCGCGGCCTCTTCGGCTGCGGA
CCCTGCCATTCCGGAGGAGGTGTGGAATATCAAACAAATGATTAAGTTGACACAGGAACATATAGAGGCCCTATTGGACAAATTTGGTGG
GGAGCATAATCCACCATCAATATATCTGGAGGCCTATGAAGAATACACCAGCAAGCTAGATGCACTCCAACAAAGAGAACAACAGTTATT
GGAATCTCTGGGGAACGGAACTGATTTTTCTGTTTCTAGCTCTGCATCAATGGATACCGTTACATCTTCTTCCTCTTCTAGCCTTTCAGT
GCTACCTTCATCTCTTTCAGTTTTTCAAAATCCCACAGATGTGGCACGGAGCAACCCCAAGTCACCACAAAAACCTATCGTTAGAGTCTT
CCTGCCCAACAAACAGAGGACAGTGGTACCTGCAAGGTGTGGAGTTACAGTCCGAGACAGTCTAAAGAAAGCACTGATGATGAGAGGTCT
AATCCCAGAGTGCTGTGCTGTTTACAGAATTCAGGATGGAGAGAAGAAACCAATTGGTTGGGACACTGATATTTCCTGGCTTACTGGAGA
AGAATTGCATGTGGAAGTGTTGGAGAATGTTCCACTTACAACACACAACTTTGTACGAAAAACGTTTTTCACCTTAGCATTTTGTGACTT
TTGTCGAAAGCTGCTTTTCCAGGGTTTCCGCTGTCAAACATGTGGTTATAAATTTCACCAGCGTTGTAGTACAGAAGTTCCACTGATGTG
TGTTAATTATGACCAACTTGATTTGCTGTTTGTCTCCAAGTTCTTTGAACACCACCCAATACCACAGGAAGAGGCGTCCTTAGCAGAGAC
TGCCCTAACATCTGGATCATCCCCTTCCGCACCCGCCTCGGACTCTATTGGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCAT
TCCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCA
TATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGCCTTCCCAGAGGAGCTTCCGGC
AGACCTGAAGCACTGGAAGCCAGCTGAGCCCCCCACTGTGGTGACTGGCAGTCTCCTAGTGAGACCAGTGAGCGACTGCTCCACCCTGCC
CTGCCTGCCACTGCCTGCGCTGTTCAACCAGGAGCCAGCCTCCGGCCAGATGCGCCTGGAGAAAACCGACCAGATTCCCATGCCTTTCTC
CAGTTCCTCGTTGAGCTGCCTGAATCTCCCTGAGGGACCCATCCAGTTTGTCCCCACCATCTCCACTCTGCCCCATGGGCTCTGGCAAAT
CTCTGAGGCTGGAACAGGGGTCTCCAGTATATTCATCTACCATGGTGAGGTGCCCCAGGCCAGCCAAGTACCCCCTCCCAGTGGATTCAC
TGTCCACGGCCTCCCAACATCTCCAGACCGGCCAGGCTCCACCAGCCCCTTCGCTCCATCAGCCACTGACCTGCCCAGCATGCCTGAACC
TGCCCTGACCTCCCGAGCAAACATGACAGAGCACAAGACGTCCCCCACCCAATGCCCGGCAGCTGGAGAGGTCTCCAACAAGCTTCCAAA
ATGGCCTGAGCCGGTGGAGCAGTTCTACCGCTCACTGCAGGACACGTATGGTGCCGAGCCCGCAGGCCCGGATGGCATCCTAGTGGAGGT
GGATCTGGTGCAGGCCAGGCTGGAGAGGAGCAGCAGCAAGAGCCTGGAGCGGGAACTGGCCACCCCGGACTGGGCAGAACGGCAGCTGGC
CCAAGGAGGCCTGGCTGAGGTGCTGTTGGCTGCCAAGGAGCACCGGCGGCCGCGTGAGACACGAGTGATTGCTGTGCTGGGCAAAGCTGG
TCAGGGCAAGAGCTATTGGGCTGGGGCAGTGAGCCGGGCCTGGGCTTGTGGCCGGCTTCCCCAGTACGACTTTGTCTTCTCTGTCCCCTG
CCATTGCTTGAACCGTCCGGGGGATGCCTATGGCCTGCAGGATCTGCTCTTCTCCCTGGGCCCACAGCCACTCGTGGCGGCCGATGAGGT
TTTCAGCCACATCTTGAAGAGACCTGACCGCGTTCTGCTCATCCTAGACGGCTTCGAGGAGCTGGAAGCGCAAGATGGCTTCCTGCACAG
CACGTGCGGACCGGCACCGGCGGAGCCCTGCTCCCTCCGGGGGCTGCTGGCCGGCCTTTTCCAGAAGAAGCTGCTCCGAGGTTGCACCCT
CCTCCTCACAGCCCGGCCCCGGGGCCGCCTGGTCCAGAGCCTGAGCAAGGCCGACGCCCTATTTGAGCTGTCCGGCTTCTCCATGGAGCA
GGCCCAGGCATACGTGATGCGCTACTTTGAGAGCTCAGGGATGACAGAGCACCAAGACAGAGCCCTGACGCTCCTCCGGGACCGGCCACT
TCTTCTCAGTCACAGCCACAGCCCTACTTTGTGCCGGGCAGTGTGCCAGCTCTCAGAGGCCCTGCTGGAGCTTGGGGAGGACGCCAAGCT
GCCCTCCACGCTCACGGGACTCTATGTCGGCCTGCTGGGCCGTGCAGCCCTCGACAGCCCCCCCGGGGCCCTGGCAGAGCTGGCCAAGCT
GGCCTGGGAGCTGGGCCGCAGACATCAAAGTACCCTACAGGAGGACCAGTTCCCATCCGCAGACGTGAGGACCTGGGCGATGGCCAAAGG
CTTAGTCCAACACCCACCGCGGGCCGCAGAGTCCGAGCTGGCCTTCCCCAGCTTCCTCCTGCAATGCTTCCTGGGGGCCCTGTGGCTGGC
TCTGAGTGGCGAAATCAAGGACAAGGAGCTCCCGCAGTACCTAGCATTGACCCCAAGGAAGAAGAGGCCCTATGACAACTGGCTGGAGGG
CGTGCCACGCTTTCTGGCTGGGCTGATCTTCCAGCCTCCCGCCCGCTGCCTGGGAGCCCTACTCGGGCCATCGGCGGCTGCCTCGGTGGA
CAGGAAGCAGAAGGTGCTTGCGAGGTACCTGAAGCGGCTGCAGCCGGGGACACTGCGGGCGCGGCAGCTGCTGGAGCTGCTGCACTGCGC
CCACGAGGCCGAGGAGGCTGGAATTTGGCAGCACGTGGTACAGGAGCTCCCCGGCCGCCTCTCTTTTCTGGGCACCCGCCTCACGCCTCC
TGATGCACATGTACTGGGCAAGGCCTTGGAGGCGGCGGGCCAAGACTTCTCCCTGGACCTCCGCAGCACTGGCATTTGCCCCTCTGGATT
GGGGAGCCTCGTGGGACTCAGCTGTGTCACCCGTTTCAGGGCTGCCTTGAGCGACACGGTGGCGCTGTGGGAGTCCCTGCAGCAGCATGG
GGAGACCAAGCTACTTCAGGCAGCAGAGGAGAAGTTCACCATCGAGCCTTTCAAAGCCAAGTCCCTGAAGGATGTGGAAGACCTGGGAAA
GCTTGTGCAGACTCAGAGGACGAGAAGTTCCTCGGAAGACACAGCTGGGGAGCTCCCTGCTGTTCGGGACCTAAAGAAACTGGAGTTTGC
GCTGGGCCCTGTCTCAGGCCCCCAGGCTTTCCCCAAACTGGTGCGGATCCTCACGGCCTTTTCCTCCCTGCAGCATCTGGACCTGGATGC
GCTGAGTGAGAACAAGATCGGGGACGAGGGTGTCTCGCAGCTCTCAGCCACCTTCCCCCAGCTGAAGTCCTTGGAAACCCTCAATCTGTC
CCAGAACAACATCACTGACCTGGGTGCCTACAAACTCGCCGAGGCCCTGCCTTCGCTCGCTGCATCCCTGCTCAGGCTAAGCTTGTACAA
TAACTGCATCTGCGACGTGGGAGCCGAGAGCTTGGCTCGTGTGCTTCCGGACATGGTGTCCCTCCGGGTGATGGACGTCCAGTACAACAA
GTTCACGGCTGCCGGGGCCCAGCAGCTCGCTGCCAGCCTTCGGAGGTGTCCTCATGTGGAGACGCTGGCGATGTGGACGCCCACCATCCC
ATTCAGTGTCCAGGAACACCTGCAACAACAGGATTCACGGATCAGCCTGAGATGATCCCAGCTGTGCTCTGGACAGGCATGTTCTCTGAG
GACACTAACCACGCTGGACCTTGAACTGGGTACTTGTGGACACAGCTCTTCTCCAGGCTGTATCCCATGAGCCTCAGCATCCTGGCACCC
GGCCCCTGCTGGTTCAGGGTTGGCCCCTGCCCGGCTGCGGAATGAACCACATCTTGCTCTGCTGACAGACACAGGCCCGGCTCCAGGCTC
CTTTAGCGCCCAGTTGGGTGGATGCCTGGTGGCAGCTGCGGTCCACCCAGGAGCCCCGAGGCCTTCTCTGAAGGACATTGCGGACAGCCA
CGGCCAGGCCAGAGGGAGTGACAGAGGCAGCCCCATTCTGCCTGCCCAGGCCCCTGCCACCCTGGGGAGAAAGTACTTCTTTTTTTTTAT
TTTTAGACAGAGTCTCACTGTTGCCCAGGCTGGCGTGCAGTGGTGCGATCTGGGTTCACTGCAACCTCCGCCTCTTGGGTTCAAGCGATT
CTTCTGCTTCAGCCTCCCGAGTAGCTGGGACTACAGGCACCCACCATCATGTCTGGCTAATTTTTCATTTTTAGTAGAGACAGGGTTTTG
CCATGTTGGCCAGGCTGGTCTCAAACTCTTGACCTCAGGTGATCCACCCACCTCAGCCTCCCAAAGTGCTGGGATTACAAGCGTGAGCCA
CTGCACCGGGCCACAGAGAAAGTACTTCTCCACCCTGCTCTCCGACCAGACACCTTGACAGGGCACACCGGGCACTCAGAAGACACTGAT
GGGCAACCCCCAGCCTGCTAATTCCCCAGATTGCAACAGGCTGGGCTTCAGTGGCAGCTGCTTTTGTCTATGGGACTCAATGCACTGACA
TTGTTGGCCAAAGCCAAAGCTAGGCCTGGCCAGATGCACCAGCCCTTAGCAGGGAAACAGCTAATGGGACACTAATGGGGCGGTGAGAGG
GGAACAGACTGGAAGCACAGCTTCATTTCCTGTGTCTTTTTTCACTACATTATAAATGTCTCTTTAATGTCACAGGCAGGTCCAGGGTTT
GAGTTCATACCCTGTTACCATTTTGGGGTACCCACTGCTCTGGTTATCTAATATGTAACAAGCCACCCCAAATCATAGTGGCTTAAAACA
ACACTCACATTTATTCTGCTCACATATCTGTCATTTGAGCAGGGCTCAGCGGGGACAGCTCCTTCTGTCCTACTCTGTGTCAGGTGGGGC
AGCTTGAGGGTTGGGCTGGTGTCACCTGAAGACTCATTCTTCTGTACGTCTGACAGGCAATGCTGGCTGTTGGCTGGGGGCCTCAGTGCC
ACTACGGAATAGTTGGCTAGGACCCCTCCATGTGGGCTAGTTGGGCTTCCTCATAGTATGGTGGCTGGGTTGGAGGGTGTCCCAAAAAGA
AAGGAGGGGATAGAGAGAGACCACTTTTCATAACCTAGCCTTAGAAGTCACACAGTATTACTTCTGCTACATATATATGTTTTAAGAGGC
AGGGTCTCACTCTGTCGCCCAGTCTGGAATGCAGTGGTATGATCACGGCTCACTGCAGCCTCAACCTCCTGGGCTAAGTGATCCTCCCAC
CTCAGCCTCCCGAATAGCTGGGACTACAGGTGTGAGTCACCAAGCCCAGTTAATCTTTAGTTTTATTTTTGTAGAGCCAGGGTCTCACTA
TGTTGCCCAGGCAGGTCTTGAACTCCTGGCCTCAAGTGATTCTCCTGCCTCAGCCTCCCAAAGTGCTGGGATTACAGGTGTGAACCACCA
CACCCAGCCCACTTCTGCCATATTCTGTTGGCCAGTGTGACAAGGATTGCTACTGTCCTACCCACCCTCCTTTCACCACATGTGCACATG
CACGTGTGTGCACGTACACACACATACACACACACGCGTGCACACACCAGAGCCCACCTTGGCTCAAGTCCTCTTTTCTGAGAGGACTTT
TCTTTGTGGCTTCCTAAAATTCAGTGGAAAATTAATTGTTTGGGGATGAGAAAGGTTGAAGCACCAAAAGCTTACCAAGGGGAATGTTTG
CCTCTGCCTCTGACACACAGCTCTGTCCTGGGAGTGAGCTGGTTTTTAGCGGAGACGGAGTCCCACCTTGGCTGCAGGGAGTCCGAAAGG
GACTTGGAAGCTCCGCTTTCTACCCAGCGAGCTGCCGGCACGACTGTTGCTTTTCACTCGGGCATAGTCTGCTCAGAAGCCCCAATTCAA
GACATCTTAGCTTACTCCTGGTGGCAGTGGGAGCTGCCTGTTCAGCTCCAGCTCACCAGCCCCAGTGCCCACAGGATCAGTCTGATTCCC
AAGCTCTGCTCCTCTCCCCAGCAAGTGAGAGCTGGGTGTCAAGAGGGTCTGAGGAATCCAGACCCGGCTGCGTGGTTGATGATCTTTGCA
GACAGGCAAGCACCTCCTGCCTCGAACTGGCTGCAAAGGGTATCAGGTGCTGCCATCCAGGTTCAGCTTGTAAATAGCTCAGGTGTCACC
CTGCAAGGGATCCCTGCACTTGCAGACTCTACAGAGGCCATGGGCCTCCTGTGTGTGCGCCTACAGGAGTGAGCACTAAGGTGTGCTCTG
ATCATCCACTGTGCCATGTGCCAGGTTTTTGGTCTGACCCACTGCTTTTGGTCTGTGTGATGATGAAATGAGGTCAGAGCCTGCAGTTAT
TAACACTAACGATTTGTTAATGATAGCTACTGTTTATTATTTTATTTAATTTTTTTGAGACAGAGTTTTCACTCTTATTGCCCACGCTGG
AGTGCAGTGGCATGATCTCGGCTCACTGCAACCTCTGCCTCCTGGGTTCAAGCAATTCTCCCACCTCAGCCTCCCAAGTAGCTGGGATTA
CAGGCATGCACCACCACGCCTGGCTAATTTTTGTATTTTTAGTAGAGATGGAGTTTCACCATGTTGGCCAGGCTGGTAATCTGCCTGCCT
TGGCCTCCCAAAGTGCTGGGATTACAGGGGTGAGCCACCGCACCCGGCCACTACTGTTTATTTAATGAGCAGATACATGCAAAGCCCTTA
TCACAGTGCAAGGGAAATTCAAAGCGCTCAGAAAGTATTAGCTCAATAAGTGATGACTGTGTGCCAGACACTGTGCTAAACTCCTACTCA
AGAGGGATAAGAGTCTAGGGGCAAGTGGCAGAGACTCTAGAACGAGATTGCCTGGGCTCAACGCCCACCTCACCACTTACTTATGCAAGC
TAGTTCTCTGTGCCTCAGTCTCCTCATTTGTAAAATGGGCATAACCACAGCACCTTCTTTATAGGATTATGTGAAGGTGTGGTGAGCTAA
TACGTTAAGAATTGGAGCTCAATAACATGTTGGCTGTCATTATTACATATATCTGTGTTTCATTCTTGCCTCTGGCTGGAATGTTCTTCC
CAGCTCTCCATATGGCTGATTTCTCATCCTTCGGGACTTGCCCCATTCTCCAACCCCATCACTAGTTTTATCTTTTTCACTTATTTATGC
AGTCTGCTCTTGTCCTAGGACATGAGCTCCAGGAGGGCGGGAAACATCTCGCTTTGTACACTGCTGTGCCCTCTGTACCCAGCAAGGCGC
CTGTGTATAATAGGTGCTCAATAACATAAAATGAACAAATAATCCTCACCTAACGGTTTCATTCATTCTGCAAATACATACTGACAGCAC
AGTCATGAATAAGATGTTCCTGCCCTGGTGAGTCTTATATTTTAGCAAATTAAAAAAACTCTTTGGACAGGGCTGCCAGGTGAGGTTGGC
CAGTCTGTACACTGCACAAAGGCACCTGGGACAAGGGGGAACATGGGGGCTGCAAACCAGTCTGGGTTCTGCTTGCCAAACTGGGAGTCC
TGGTGTGGAGCCTTTTAACCCAGAGGGGCATCTTTTCGTAGTTAACGCACAGTCATCGTAAGATGTGGATAAATTACTGTCTCCGTGTCA
CAGATCTAAGTGATACTTATAGTCACACTCCTATAAAGGAATGGACTTCTGACTTCTTTGGAGGACCTCTCTGCAGGGACAGGCACAGTG
TGCCGGAAGTGCCCCTGAACCCCATTTGTCAGGTGGTAAAGCGCTGCTCGGAGGAATCAGGGCATGATAGTGCAATTCCATGTCCAGTGG
ATTGTAAGTCCACGCACCTTCCAAATGGTCACTCTTCCTCGCAGGCCTCTCTCTGCATACAAATGTCTCCCTCCTGACGCTCACCTTTTT
CCCTGGGGCTCTCAAATGTCTTCTTTTCAGATTTCGTAGCTTTTCTTTCTTTAGCATCACTTGAGGGCAAGTGGTGCTCCAACTGTCTCC
CCCCAGAGTTCTGCCGCCTGTACTCTCCCACACCTCAGTCTCCTCGCCTGTAGAAAGGGGTCAATCGTTTGAACCCTGCTTCACTTGGTG
TGTATGTGAAGGTGCTTTGAAATCAAGTGCTCTGCAAACTGGAGAGAATTACTGCTTGTATTCCGTGAAACTACAAGCTCCCAATTCCAC
TCATTTAATCCCTCTCTTGCTCTGTTGCCCAGGCTGGAATGCAGTGGCATGATCTCAACTCACTGCAACCTCTGCCTCCCTGGTTTCAAG
CAATTCTCCTGCCTCAGCCTCCCGAGTAGCTGGGACTATAAGTGTGCGCCACTATGCCTGGCTAATTTTTTTGTATTTTTAGTAGAGATG
GGGTTTCACCGTGGTGGCCAGGCTGGTCTCGAACTCCTAACCTCAAGTGATCTGCCCGCCTCGGCCTTCCAAAGTGCTGGGATTACAGGC
ATGAGCCACCATGCCAAGCCCTTCCCCCCTATCTTTAATGAAGGTCTACCATGTGCCTGACACAGGGGATACCCACCCCCACTTCTATGG
GATTCAGGCCTGGTTTCCAGCTTGGCCTTCAGGCTTTTCCCACCACACCCCAAATGCTGTCCCTGGCTTGTGGAGTGGGGCAGGGGGCCA
GCCTGGGACTTTCACGCCAGCCCGACTGGGGCAGACTCTCTCAACCCCACTGGATCTTCTGCTGTTTGTCAGCCACAAGGTTCTGCCTAG
AACTCCTTTCCCGAATCTCAAAGTTAAAAAAAAAGGCAGGGCCCCAGGGGTTGGAGTTGCATACATTTTTTTTTAATCCAAAGAAGTAAG
CCTCCTAAGTATTGCTTAGACAGGTTTATCAGAATTAAGTAGGCACAACACTCATACTTTCAGAAAAGCATTTCCAGCCAGGGGAGTAAC
GTGGCACTCACCAGCATGATGTCTGTTTTGCCAACTTGCTGAAGAACGAGTAACCTGAAATGAAGGAGCGAGAATCCCACCCTCAGCCCC
CCAACAGCTTCCTCAGCTTCTTTTTCTTCTGAGTCACCCCTGAAACAGTCGCTGCATCTAAGACCAGCCTCGGGCTAAACCCAGCTGGCC
TGAAGGCTCAACTCACATCAAACGGAGCTGGGAGTCGCTTTTGCGTGTGTCCGCAGTTTGAAGTGTCCTCTCCGAAGGTGAAGTGGGGGA
AGCAGGTGCGCTCCGGGATGAAGTGCAGGGAGGCAAACTCTGGCTGGGTTCCTGTAAACATCCATCGCAGCTGCAAATAATCAGAAGCCA
AGGCCAGGCCATCGATTTGACACTGCAGGCAGATGAGGTCTTGGGATGCCTCTTGCGTTCCCCCTTCTGTGGGAGCAGGTGCCTTCCCAA
CCTCAGCACTCAGTCCCAATCTCTCTTCCACTCTCCTGGGTTCAAACAGGAACCTCTCTGTTGGCACGAAGCTTTTGAGGGGAGCAGGTC
TAACAAGAAGGAAAAAGGGGGGTTATTAGCACGGAAGCCCCACCCTGCCACCAGGTTGGCTGGGGACAGGGACCAATCCACCAGGCTCGG
GAGGCTTGGGGTGGGGCAGGGAAGTCTTCCTCCATCCCTCAAATTTAGGGAACCACTGGGAGCCCCAGACTCAGGCTGAAAATGTCTTTC

>10118_10118_1_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000324288_length(amino acids)=1377AA_BP=392
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD
ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS
LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ
RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR
DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGAFPEELPADLKHWKPAEPPTVVTGSLLVRPVSDCSTLPCLPLPALFNQEPASGQMRLE
KTDQIPMPFSSSSLSCLNLPEGPIQFVPTISTLPHGLWQISEAGTGVSSIFIYHGEVPQASQVPPPSGFTVHGLPTSPDRPGSTSPFAPS
ATDLPSMPEPALTSRANMTEHKTSPTQCPAAGEVSNKLPKWPEPVEQFYRSLQDTYGAEPAGPDGILVEVDLVQARLERSSSKSLERELA
TPDWAERQLAQGGLAEVLLAAKEHRRPRETRVIAVLGKAGQGKSYWAGAVSRAWACGRLPQYDFVFSVPCHCLNRPGDAYGLQDLLFSLG
PQPLVAADEVFSHILKRPDRVLLILDGFEELEAQDGFLHSTCGPAPAEPCSLRGLLAGLFQKKLLRGCTLLLTARPRGRLVQSLSKADAL
FELSGFSMEQAQAYVMRYFESSGMTEHQDRALTLLRDRPLLLSHSHSPTLCRAVCQLSEALLELGEDAKLPSTLTGLYVGLLGRAALDSP
PGALAELAKLAWELGRRHQSTLQEDQFPSADVRTWAMAKGLVQHPPRAAESELAFPSFLLQCFLGALWLALSGEIKDKELPQYLALTPRK
KRPYDNWLEGVPRFLAGLIFQPPARCLGALLGPSAAASVDRKQKVLARYLKRLQPGTLRARQLLELLHCAHEAEEAGIWQHVVQELPGRL
SFLGTRLTPPDAHVLGKALEAAGQDFSLDLRSTGICPSGLGSLVGLSCVTRFRAALSDTVALWESLQQHGETKLLQAAEEKFTIEPFKAK
SLKDVEDLGKLVQTQRTRSSSEDTAGELPAVRDLKKLEFALGPVSGPQAFPKLVRILTAFSSLQHLDLDALSENKIGDEGVSQLSATFPQ
LKSLETLNLSQNNITDLGAYKLAEALPSLAASLLRLSLYNNCICDVGAESLARVLPDMVSLRVMDVQYNKFTAAGAQQLAASLRRCPHVE

--------------------------------------------------------------
>10118_10118_2_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000381835_length(transcript)=3025nt_BP=1238nt
CGCCTCCCTTCCCCCTCCCCGCCCGACAGCGGCCGCTCGGGCCCCGGCTCTCGGTTATAAGATGGCGGCGCTGAGCGGTGGCGGTGGTGG
CGGCGCGGAGCCGGGCCAGGCTCTGTTCAACGGGGACATGGAGCCCGAGGCCGGCGCCGGCGCCGGCGCCGCGGCCTCTTCGGCTGCGGA
CCCTGCCATTCCGGAGGAGGTGTGGAATATCAAACAAATGATTAAGTTGACACAGGAACATATAGAGGCCCTATTGGACAAATTTGGTGG
GGAGCATAATCCACCATCAATATATCTGGAGGCCTATGAAGAATACACCAGCAAGCTAGATGCACTCCAACAAAGAGAACAACAGTTATT
GGAATCTCTGGGGAACGGAACTGATTTTTCTGTTTCTAGCTCTGCATCAATGGATACCGTTACATCTTCTTCCTCTTCTAGCCTTTCAGT
GCTACCTTCATCTCTTTCAGTTTTTCAAAATCCCACAGATGTGGCACGGAGCAACCCCAAGTCACCACAAAAACCTATCGTTAGAGTCTT
CCTGCCCAACAAACAGAGGACAGTGGTACCTGCAAGGTGTGGAGTTACAGTCCGAGACAGTCTAAAGAAAGCACTGATGATGAGAGGTCT
AATCCCAGAGTGCTGTGCTGTTTACAGAATTCAGGATGGAGAGAAGAAACCAATTGGTTGGGACACTGATATTTCCTGGCTTACTGGAGA
AGAATTGCATGTGGAAGTGTTGGAGAATGTTCCACTTACAACACACAACTTTGTACGAAAAACGTTTTTCACCTTAGCATTTTGTGACTT
TTGTCGAAAGCTGCTTTTCCAGGGTTTCCGCTGTCAAACATGTGGTTATAAATTTCACCAGCGTTGTAGTACAGAAGTTCCACTGATGTG
TGTTAATTATGACCAACTTGATTTGCTGTTTGTCTCCAAGTTCTTTGAACACCACCCAATACCACAGGAAGAGGCGTCCTTAGCAGAGAC
TGCCCTAACATCTGGATCATCCCCTTCCGCACCCGCCTCGGACTCTATTGGGCCCCAAATTCTCACCAGTCCGTCTCCTTCAAAATCCAT
TCCAATTCCACAGCCCTTCCGACCAGCAGATGAAGATCATCGAAATCAATTTGGGCAACGAGACCGATCCTCATCAGCTCCCAATGTGCA
TATAAACACAATAGAACCTGTCAATATTGATGACTTGATTAGAGACCAAGGATTTCGTGGTGATGGAGCCTTCCCAGAGGAGCTTCCGGC
AGACCTGAAGCACTGGAAGCCAGTGCCTTTCTCCAGTTCCTCGTTGAGCTGCCTGAATCTCCCTGAGGGACCCATCCAGTTTGTCCCCAC
CATCTCCACTCTGCCCCATGGGCTCTGGCAAATCTCTGAGGCTGGAACAGGGGTCTCCAGTATATTCATCTACCATGGTGAGGTGCCCCA
GGCCAGCCAAGTACCCCCTCCCAGTGGATTCACTGTCCACGGCCTCCCAACATCTCCAGACCGGCCAGGCTCCACCAGCCCCTTCGCTCC
ATCAGCCACTGACCTGCCCAGCATGCCTGAACCTGCCCTGACCTCCCGAGCAAACATGACAGAGCACAAGACGTCCCCCACCCAATGCCC
GGCAGCTGGAGAGGTCTCCAACAAGCTTCCAAAATGGCCTGGTCTAGCCTGGTCACCGTGCCTGGGTCTGAGGCCCTCCCTCCACAGGGC
TGCCTTGAGCGACACGGTGGCGCTGTGGGAGTCCCTGCAGCAGCATGGGGAGACCAAGCTACTTCAGGCAGCAGAGGAGAAGTTCACCAT
CGAGCCTTTCAAAGCCAAGTCCCTGAAGGATGTGGAAGACCTGGGAAAGCTTGTGCAGACTCAGAGGACGAGAAGTTCCTCGGAAGACAC
AGCTGGGGAGCTCCCTGCTGTTCGGGACCTAAAGAAACTGGAGTTTGCGCTGGGCCCTGTCTCAGGCCCCCAGGCTTTCCCCAAACTGGT
GCGGATCCTCACGGCCTTTTCCTCCCTGCAGCATCTGGACCTGGATGCGCTGAGTGAGAACAAGATCGGGGACGAGGGTGTCTCGCAGCT
CTCAGCCACCTTCCCCCAGCTGAAGTCCTTGGAAACCCTCAATCTGTCCCAGAACAACATCACTGACCTGGGTGCCTACAAACTCGCCGA
GGCCCTGCCTTCGCTCGCTGCATCCCTGCTCAGGCTAAGCTTGTACAATAACTGCATCTGCGACGTGGGAGCCGAGAGCTTGGCTCGTGT
GCTTCCGGACATGGTGTCCCTCCGGGTGATGGACGTCCAGTACAACAAGTTCACGGCTGCCGGGGCCCAGCAGCTCGCTGCCAGCCTTCG
GAGGTGTCCTCATGTGGAGACGCTGGCGATGTGGACGCCCACCATCCCATTCAGTGTCCAGGAACACCTGCAACAACAGGATTCACGGAT
CAGCCTGAGATGATCCCAGCTGTGCTCTGGACAGGCATGTTCTCTGAGGACACTAACCACGCTGGACCTTGAACTGGGTACTTGTGGACA
CAGCTCTTCTCCAGGCTGTATCCCATGAGCCTCAGCATCCTGGCACCCGGCCCCTGCTGGTTCAGGGTTGGCCCCTGCCCGGCTGCGGAA
TGAACCACATCTTGCTCTGCTGACAGACACAGGCCCGGCTCCAGGCTCCTTTAGCGCCCAGTTGGGTGGATGCCTGGTGGCAGCTGCGGT
CCACCCAGGAGCCCCGAGGCCTTCTCTGAAGGACATTGCGGACAGCCACGGCCAGGCCAGAGGGAGTGACAGAGGCAGCCCCATTCTGCC
TGCCCAGGCCCCTGCCACCCTGGGGAGAAAGTACTTCTTTTTTTTTATTTTTAGACAGAGTCTCACTGTTGCCCAGGCTGGCGTGCAGTG
GTGCGATCTGGGTTCACTGCAACCTCCGCCTCTTGGGTTCAAGCGATTCTTCTGCTTCAGCCTCCCGAGTAGCTGGGACTACAGGCACCC

>10118_10118_2_BRAF-CIITA_BRAF_chr7_140487348_ENST00000288602_CIITA_chr16_10995371_ENST00000381835_length(amino acids)=793AA_BP=392
MAALSGGGGGGAEPGQALFNGDMEPEAGAGAGAAASSAADPAIPEEVWNIKQMIKLTQEHIEALLDKFGGEHNPPSIYLEAYEEYTSKLD
ALQQREQQLLESLGNGTDFSVSSSASMDTVTSSSSSSLSVLPSSLSVFQNPTDVARSNPKSPQKPIVRVFLPNKQRTVVPARCGVTVRDS
LKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPLTTHNFVRKTFFTLAFCDFCRKLLFQGFRCQTCGYKFHQ
RCSTEVPLMCVNYDQLDLLFVSKFFEHHPIPQEEASLAETALTSGSSPSAPASDSIGPQILTSPSPSKSIPIPQPFRPADEDHRNQFGQR
DRSSSAPNVHINTIEPVNIDDLIRDQGFRGDGAFPEELPADLKHWKPVPFSSSSLSCLNLPEGPIQFVPTISTLPHGLWQISEAGTGVSS
IFIYHGEVPQASQVPPPSGFTVHGLPTSPDRPGSTSPFAPSATDLPSMPEPALTSRANMTEHKTSPTQCPAAGEVSNKLPKWPGLAWSPC
LGLRPSLHRAALSDTVALWESLQQHGETKLLQAAEEKFTIEPFKAKSLKDVEDLGKLVQTQRTRSSSEDTAGELPAVRDLKKLEFALGPV
SGPQAFPKLVRILTAFSSLQHLDLDALSENKIGDEGVSQLSATFPQLKSLETLNLSQNNITDLGAYKLAEALPSLAASLLRLSLYNNCIC

--------------------------------------------------------------

Top

Fusion Gene PPI Analysis for BRAF-CIITA


check button Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in

ChiPPI page.


check button Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160)
HgeneHgene's interactorsTgeneTgene's interactors


check button - Retained PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenStill interaction with


check button - Lost PPIs in in-frame fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


check button - Retained PPIs, but lost function due to frame-shift fusion.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenInteraction lost with


Top

Related Drugs for BRAF-CIITA


check button Drugs targeting genes involved in this fusion gene.
(DrugBank Version 5.1.8 2021-05-08)
PartnerGeneUniProtAccDrugBank IDDrug nameDrug activityDrug typeDrug status
HgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB08881VemurafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB08896RegorafenibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB14840RipretinibInhibitorSmall moleculeApproved
HgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB00398SorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB08912DabrafenibAntagonist|InhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB11718EncorafenibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational
HgeneBRAFP15056DB12010FostamatinibInhibitorSmall moleculeApproved|Investigational

Top

Related Diseases for BRAF-CIITA


check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneBRAFC0025202melanoma24CGI;CTD_human;UNIPROT
HgeneBRAFC1275081Cardio-facio-cutaneous syndrome14CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET;UNIPROT
HgeneBRAFC0009402Colorectal Carcinoma8CTD_human;UNIPROT
HgeneBRAFC0028326Noonan Syndrome8CLINGEN;CTD_human;GENOMICS_ENGLAND;ORPHANET
HgeneBRAFC0238463Papillary thyroid carcinoma8CTD_human;ORPHANET
HgeneBRAFC0040136Thyroid Neoplasm6CGI;CTD_human
HgeneBRAFC0151468Thyroid Gland Follicular Adenoma6CTD_human
HgeneBRAFC0175704LEOPARD Syndrome6CLINGEN;GENOMICS_ENGLAND
HgeneBRAFC0549473Thyroid carcinoma6CGI;CTD_human
HgeneBRAFC3150970NOONAN SYNDROME 75CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneBRAFC0009404Colorectal Neoplasms4CTD_human
HgeneBRAFC3150971LEOPARD SYNDROME 34CTD_human;GENOMICS_ENGLAND;UNIPROT
HgeneBRAFC1519086Pilomyxoid astrocytoma3ORPHANET
HgeneBRAFC0004565Melanoma, B162CTD_human
HgeneBRAFC0009075Melanoma, Cloudman S912CTD_human
HgeneBRAFC0018598Melanoma, Harding-Passey2CTD_human
HgeneBRAFC0023443Hairy Cell Leukemia2CGI;ORPHANET
HgeneBRAFC0025205Melanoma, Experimental2CTD_human
HgeneBRAFC0033578Prostatic Neoplasms2CTD_human
HgeneBRAFC0152013Adenocarcinoma of lung (disorder)2CGI;CTD_human
HgeneBRAFC0376358Malignant neoplasm of prostate2CTD_human
HgeneBRAFC0587248Costello syndrome (disorder)2CLINGEN;CTD_human
HgeneBRAFC3501843Nonmedullary Thyroid Carcinoma2CTD_human
HgeneBRAFC3501844Familial Nonmedullary Thyroid Cancer2CTD_human
HgeneBRAFC0002448Ameloblastoma1CTD_human
HgeneBRAFC0004114Astrocytoma1CTD_human
HgeneBRAFC0010276Craniopharyngioma1CTD_human;ORPHANET
HgeneBRAFC0011860Diabetes Mellitus, Non-Insulin-Dependent1CTD_human
HgeneBRAFC0017638Glioma1CGI;CTD_human
HgeneBRAFC0019621Histiocytosis, Langerhans-Cell1CGI;ORPHANET
HgeneBRAFC0022665Kidney Neoplasm1CTD_human
HgeneBRAFC0023903Liver neoplasms1CTD_human
HgeneBRAFC0024232Lymphatic Metastasis1CTD_human
HgeneBRAFC0024694Mandibular Neoplasms1CTD_human
HgeneBRAFC0027659Neoplasms, Experimental1CTD_human
HgeneBRAFC0027962Melanocytic nevus1GENOMICS_ENGLAND
HgeneBRAFC0036920Sezary Syndrome1CTD_human
HgeneBRAFC0041409Turner Syndrome, Male1CTD_human
HgeneBRAFC0079773Lymphoma, T-Cell, Cutaneous1CTD_human
HgeneBRAFC0205768Subependymal Giant Cell Astrocytoma1CTD_human
HgeneBRAFC0206686Adrenocortical carcinoma1CTD_human
HgeneBRAFC0206754Neuroendocrine Tumors1CTD_human
HgeneBRAFC0259783mixed gliomas1CTD_human
HgeneBRAFC0278875Adult Craniopharyngioma1CTD_human
HgeneBRAFC0280783Juvenile Pilocytic Astrocytoma1CTD_human
HgeneBRAFC0280785Diffuse Astrocytoma1CTD_human
HgeneBRAFC0334579Anaplastic astrocytoma1CGI;CTD_human
HgeneBRAFC0334580Protoplasmic astrocytoma1CTD_human
HgeneBRAFC0334581Gemistocytic astrocytoma1CTD_human
HgeneBRAFC0334582Fibrillary Astrocytoma1CTD_human
HgeneBRAFC0334583Pilocytic Astrocytoma1CGI;CTD_human
HgeneBRAFC0338070Childhood Cerebral Astrocytoma1CTD_human
HgeneBRAFC0345904Malignant neoplasm of liver1CTD_human
HgeneBRAFC0376407Granulomatous Slack Skin1CTD_human
HgeneBRAFC0406803Syringocystadenoma Papilliferum1GENOMICS_ENGLAND
HgeneBRAFC0431128Papillary craniopharyngioma1CTD_human
HgeneBRAFC0431129Adamantinous Craniopharyngioma1CTD_human
HgeneBRAFC0547065Mixed oligoastrocytoma1CTD_human
HgeneBRAFC0555198Malignant Glioma1CTD_human
HgeneBRAFC0596263Carcinogenesis1CTD_human
HgeneBRAFC0684249Carcinoma of lung1CGI;UNIPROT
HgeneBRAFC0740457Malignant neoplasm of kidney1CTD_human
HgeneBRAFC0750935Cerebral Astrocytoma1CTD_human
HgeneBRAFC0750936Intracranial Astrocytoma1CTD_human
HgeneBRAFC0751061Craniopharyngioma, Child1CTD_human
HgeneBRAFC0920269Microsatellite Instability1CTD_human
HgeneBRAFC1527404Female Pseudo-Turner Syndrome1CTD_human
HgeneBRAFC1704230Grade I Astrocytoma1CTD_human
HgeneBRAFC1721098Replication Error Phenotype1CTD_human
HgeneBRAFC2239176Liver carcinoma1CTD_human
HgeneBRAFC4551484Leopard Syndrome 11GENOMICS_ENGLAND
HgeneBRAFC4551602Noonan Syndrome 11CTD_human
HgeneBRAFC4721532Lymphoma, Non-Hodgkin, Familial1UNIPROT
HgeneBRAFC4733333familial non-medullary thyroid cancer1GENOMICS_ENGLAND
TgeneC2931418Bare lymphocyte syndrome 25CTD_human;ORPHANET;UNIPROT
TgeneC0001403Addison Disease1CTD_human
TgeneC1859534Bare Lymphocyte Syndrome, Type II, Complementation Group A1GENOMICS_ENGLAND
TgeneC2930967Gastro-enteropancreatic neuroendocrine tumor1CTD_human